Utility of NT-proBNP as a rule-out test for left ventricular dysfunction in very old people with limiting dyspnoea: the Newcastle 85+ Study

BMC Cardiovascular Disorders

Bernard Keavney⁵  Thomas BL Kirkwood²  Louise Robinson⁴  Guy MacGowan⁶  Carmen Martin-Ruiz²  Dermot Neely³  Antoinette Kenny¹  Karen Davies²  Fahad Yousaf²  Andrew Kingston²  Joanna Collerton² 

[1] Department of Cardiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK;Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK;Department of Clinical Biochemistry, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK;Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK;Institute of Cardiovascular Sciences, The University of Manchester, Manchester, UK;Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

关键词: Aged, 80 and over;    Sensitivity and specificity;    Natriuretic peptides;    Diastolic dysfunction;    Systolic dysfunction;   

Others  :  1088444
DOI  :  10.1186/1471-2261-14-128

 received in 2014-06-17, accepted in 2014-09-18,  发布年份 2014

【 摘 要 】

Background

Guidelines advocate using B-type natriuretic peptides in the diagnostic work-up of suspected heart failure (HF). Their main role is to limit echocardiography rates by ruling out HF/LV dysfunction where peptide level is low. Recommended rule-out cut points vary between guidelines. The utility of B-type natriuretic peptides in the very old (85+) requires further investigation, with optimal cut points yet to be established. We examined NT-proBNP's utility, alone and in combination with history of myocardial infarction (MI), as a rule-out test for LV dysfunction in very old people with limiting dyspnoea.

Methods

Design: Cross-sectional analysis.

Setting: Population-based sample; North-East England.

Participants: 155 people (aged 87-89) with limiting dyspnoea.

Measures: Dyspnoea assessed by questionnaire. Domiciliary echocardiography performed; LV systolic/diastolic function graded. NT-proBNP measured (Roche Diagnostics). Receiver operating characteristic analyses examined NT-proBNP's diagnostic accuracy for LV dysfunction.

Results

AUC for LVEF less than or equal to 50% was poor (0.58, 95% CI 0.49-0.65), but good for LVEF less than or equal to 40% (0.80, 95% CI 0.73-0.86). At ESC cut point (125ng/l), few cases of systolic dysfunction were missed (NPV 94-100%, depending on severity), but echocardiography (88%) and false positive rates (56-81 per 100 screened) were high. At NICE cut point (400ng/l), echocardiography (51%) and false positive rates (33-45) were lower; exclusionary performance was good for LVEF less than or equal to 40% (1 case missed per 100 screened, 15% of cases; NPV 97%), but poor for LVEF less than or equal to 50% (16 cases missed per 100 screened, 45% of cases; NPV 68%). Incorporating isolated moderate/severe diastolic dysfunction into target condition increased the proportion of cases missed (lower NPV), whilst improving case detection. Incorporating MI history as an additional referral prompt slightly reduced the number of cases missed at expense of higher echocardiography and false positive rates.

Conclusions

High echocardiography rates and poor exclusionary performance for mild degrees of systolic dysfunction and for diastolic dysfunction limit NT-proBNP's utility as a rule-out test for LV dysfunction in very old people with limiting dyspnoea. Incorporating MI history as an additional echocardiography prompt yields no overall benefit compared to using NT-proBNP level alone.

【 授权许可】

   
2014 Collerton et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]United Nations Department of Economic and Social Affairs. Population Division: World Population Ageing: 2009. [http://www.un.org/esa/population/publications/WPA2009/WPA2009_WorkingPaper.pdf webcite]
• [2]Wong CY, Chaudhry SI, Desai MM, Krumholz HM: Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med 2011, 124(2):136-143.
• [3]Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators N Engl J Med 1992, 327(10):685-691.
• [4]Tresch DD: Clinical manifestations, diagnostic assessment, and etiology of heart failure in elderly patients. Clin Geriatr Med 2000, 16(3):445-456.
• [5]Remme WJ, McMurray JJ, Hobbs FD, Cohen-Solal A, Lopez-Sendon J, Boccanelli A, Zannad F, Rauch B, Keukelaar K, Macarie C, Ruzyllo W, Cline C, Shape Study Group: Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J 2008, 29(14):1739-1752.
• [6]Senni M, Rodeheffer RJ, Tribouilloy CM, Evans JM, Jacobsen SJ, Bailey KR, Redfield MM: Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol 1999, 33(1):164-170.
• [7]NHS National Institute for Health and Care Excellence: Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. [http://www.nice.org.uk/guidance/cg108 webcite]
• [8]McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33(14):1787-1847.
• [9]Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Mant D, McManus RJ, Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD: Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009, 13(32):1-207.
• [10]Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr: Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006, 47(2):345-353.
• [11]Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, Pedersen F: The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003, 89(7):745-751.
• [12]Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr: Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004, 109(25):3176-3181.
• [13]Hogg K, Swedberg K, McMurray J: Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004, 43(3):317-327.
• [14]Yousaf F, Collerton J, Kingston A, Kenny A, Davies K, Jagger C, Robinson L, Kirkwood TB, Keavney B: Prevalence of left ventricular dysfunction in a UK community sample of very old people: the Newcastle 85+ study. Heart 2012, 98(19):1418-1423.
• [15]Collerton J, Davies K, Jagger C, Kingston A, Bond J, Eccles MP, Robinson LA, Martin-Ruiz C, von Zglinicki T, James OFW, Kirkwood TBL: Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ 2009, 339:b4904.
• [16]Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18(12):1440-1463.
• [17]British Society of Echocardiography Education Committee (Masani N, Wharton G, Allen J, Chambers J, Graham J, Jones R, Rana B, Steeds R): Echocardiography: Guidelines for Chamber Quantification. 2010.
• [18]DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44(3):837-845.
• [19]Hildebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, Gustafsson F, Januzzi J, Rosenberg J, Senior R, Richards M: Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J 2010, 31(15):1881-1889.
• [20]Rutten FH, Cramer MJ, Zuithoff NP, Lammers JW, Verweij W, Grobbee DE, Hoes AW: Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 2007, 9(6–7):651-659.
• [21]Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS: Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003, 108(8):977-982.
• [22]Manzano L, Escobar C, Cleland JG, Flather M: Diagnosis of elderly patients with heart failure. Eur J Heart Fail 2012, 14(10):1097-1103.
• [23]Vaes B, de Ruijter W, Gussekloo J, Degryse J: The accuracy of plasma natriuretic peptide levels for diagnosis of cardiac dysfunction and chronic heart failure in community-dwelling elderly: a systematic review. Age Ageing 2009, 38(6):655-662.
• [24]Olofsson M, Boman K: Usefulness of natriuretic peptides in primary health care: an exploratory study in elderly patients. Scand J Prim Health Care 2010, 28(1):29-35.
• [25]Chenevier-Gobeaux C, Delerme S, Allo JC, Arthaud M, Claessens YE, Ekindjian OG, Riou B, Ray P: B-type natriuretic peptides for the diagnosis of congestive heart failure in dyspneic oldest-old patients. Clin Biochem 2008, 41(13):1049-1054.
• [26]Oudejans I, Mosterd A, Zuithoff NP, Hoes AW: Applicability of current diagnostic algorithms in geriatric patients suspected of new, slow onset heart failure. Age Ageing 2012, 41(3):309-316.
• [27]van Bemmel T, Delgado V, Bax JJ, Gussekloo J, Blauw GJ, Westendorp RG, Holman ER: Impact of valvular heart disease on activities of daily living of nonagenarians: the Leiden 85-plus study a population based study. BMC Geriatr 2010, 10:17. BioMed Central Full Text
• [28]Alehagen U, Svensson E, Dahlstrom U: Natriuretic peptide biomarkers as information indicators in elderly patients with possible heart failure followed over six years: a head-to-head comparison of four cardiac natriuretic peptides. J Card Fail 2007, 13(6):452-461.
• [29]Goode KM, Clark AL, Cleland JG: Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width. Int J Cardiol 2008, 130(3):426-437.
• [30]Park HJ, Baek SH, Jang SW, Kim DB, Shin DI, Shin WS, Kim PJ, Jung HB, Jung HO, Seung KB, Choi KB: Direct comparison of B-type natriuretic peptide and N-terminal pro-BNP for assessment of cardiac function in a large population of symptomatic patients. Int J Cardiol 2010, 140(3):336-343.
• [31]Landray MJ, Lehman R, Arnold I: Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study. BMJ 2000, 320(7240):985-986.
• [32]Sivakumar R, Wellsted D, Parker K, Lynch M, Ghosh P, Khan SA: Utility of N terminal pro brain natriuretic peptide in elderly patients. Postgrad Med J 2006, 82(965):220-223.
• [33]Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E, Gardetto N, Garcia A, DeMaria A, Maisel AS: Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001, 111(4):274-279.
• [34]Mason JM, Hancock HC, Close H, Murphy JJ, Fuat A, de Belder M, Singh R, Teggert A, Wood E, Brennan G, Hussain N, Kumar N, Manshani N, Hodges D, Wilson D, Hungin AP: Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFinCH) diagnostic accuracy study. PLoS ONE 2013, 8(1):e53560.
• [35]Tait L, Roalfe AK, Mant J, Cowie MR, Deeks JJ, Iles R, Barton PM, Taylor CJ, Derit M, Hobbs FD: The REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical decision rule, NT-proBNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design. BMC Cardiovasc Disord 2012, 12:97. BioMed Central Full Text
• [36]Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ: The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002, 4(3):361-371.